
AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Cohu’s story today is about whether you believe its semiconductor test platforms can convert AI, automotive and computing demand into sustainable profits, despite current losses. The broad Russell growth index additions mainly increase visibility and liquidity, but do not materially change the near term catalyst around AI and high performance computing orders, or the key risk that earnings remain negative while the company executes capacity moves and customer ramps.
Among recent announcements, the April 2026 follow on Eclipse orders totaling about US$30,000,000 for HPC and AI processor testing stand out as most relevant. These orders speak directly to the same AI and computing themes that underpin Cohu’s growth oriented index inclusion, while also highlighting the execution risk if a few large AI programs slow or fail to scale as expected.
Yet against these positives, investors should still weigh the concentration of AI related programs and the operational risks in Cohu’s manufacturing shift...
Read the full narrative on Cohu (it's free!)
Cohu's narrative projects $823.8 million revenue and $51.8 million earnings by 2029.
Uncover how Cohu's forecasts yield a $60.29 fair value, a 18% downside to its current price.
By contrast, the most cautious analysts were assuming about US$730,000,000 in 2029 revenue and US$36,600,000 earnings, which frames a far tougher path than the Russell inclusion might suggest.
Explore 2 other fair value estimates on Cohu - why the stock might be worth less than half the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com